American Association for Cancer Research Annual Meeting
American Association for Cancer Research Annual Meeting
April 18, 2016
2 min watch

VIDEO: Gene signature may guide adjuvant chemotherapy use in early-stage breast cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

NEW ORLEANS — Lajos Pusztai, MD, DPhil, chief of breast medical oncology and co-director of the genetics, genomics and epigenetics program at Yale Cancer Center, spoke with HemOnc Today about the potential implications of the MINDACT trial.

Results of the randomized phase 3 trial showed a 70-gene signature called MammaPrint can help predict which patients with early-stage breast cancer will derive the most benefit from adjuvant chemotherapy.